ECE2007 Poster Presentations (1) (659 abstracts)
Prognostic significance of BRAF mutation in patients affected by papillary thyroid carcinoma with a follow up of 20 years
David Viola 1 , Cristina Romei 1 , Agnese Biagini 1 , Laura Agate 1 , Eleonora Molinaro 1 , Raffaele Ciampi 1 , Giulia Renzini 1 , Riccardo Giannini 2 , Clara Ugolini 1 , Piero Berti 3 , Aldo Pinchera 1 & Rossella Elisei 1
1Department of Endocrinology, University of Pisa, Pisa, Italy; 2Department of Oncology, University of Pisa, Pisa, Italy; 3Department of Surgery, University of Pisa, P, Italy.
BRAFV600E is the most common mutation in papillary thyroid carcinoma (PTC). Anatomo-patology and clinical features of PTC with BRAFV600E are well described in literature.
Aim of this study was to examine the prognostic significance of BRAFV600E in patients with PTC and a follow-up of 15-20 years.
Genomic DNA was purified from 67 paraffin-embedded tumoral tissue. A PCR-SSCP analysis of exon 15 of BRAF was performed. Direct sequencing of SSCP positive cases was made. BRAFV600E was found in 23/67 cases (34%): 18 females (78%) and 5 males (22%), with a mean age of 48.9±16.2 yrs (median: 50 yrs). Ten were in class 1 (43.6%), 6 in class 2 (26%), 4 in class 3 (17.4%) and 3 in class 4 (13%). Among the 44 patients without BRAFV600E 37 were females (84%) and 7 were males (16%), with a mean age of 42.2±15.36 (median: 39.5 yrs). Twenty-seven were in class 1 (61.4%), 12 in class 2 (27.3%) and 5 in class 3 (11.3%). At the end of the study 54 patients (80.5%) were free of disease, 9 (13.5%) had persistent disease and 4 (6%) died of thyroid carcinoma. Among the 44 patients without BRAFV600E mutation, 41 (93.2%) were free of disease, 2 (4.5%) had persistent disease and only 1 (2.3%) died for PTC at the end of follow-up. Between the 23 patients BRAFV600E, 13 (56.5%) were free of disease, 7 (30.5%) had persistent disease and 3 (13%) died for thyroid carcinoma. The statistical analysis showed a positive correlation between BRAFV600E mutation and the outcome of the patients (p=0.0003). Older age, male sex, advanced tumoral class, loco-regional and/or distant metastasis were more frequent in the patients with BRAFV600E without statistically significant correlation.
In conclusion our data suggest that BRAFV600E is an unfavorable prognostic factor in patients affected by PTC.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more